South Delhi Pharma, New Delhi, India
Erleada (apalutamide)
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
Facts of Erleada (apalutamide)
Product: ERLEADA® (apalutamide) tablets, for oral use
Initial U.S. Approval – 2018
Strength: Tablets: 60 mg
Company: Janssen
Indication: prostate cancer
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Erleada (apalutamide)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Erleada (apalutamide) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
What Erleada is?
ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with
• metastatic castration-sensitive prostate cancer.
• non-metastatic castration-resistant prostate cancer
What Apalutamide is?
Apalutamide, sold under the brand name Erleada, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
Apalutamide is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of NM-CRPC. It is also a promising potential treatment for metastatic castration-resistant prostate cancer (mCRPC), which the NSAA enzalutamide and the androgen synthesis inhibitor abiraterone acetate are used to treat.
